Abstract
There is a strong impetus in the psychosis research field to develop interventions that aim to prevent the onset of psychotic disorders. Over the past 15 years there has been a tremendous development in the work aimed at understanding the pre-psychotic period. More recently there has been a focus on developing and testing treatments both pharmacological and psychological that could potentially prevent or delay the onset of psychosis. One of the psychological treatments that has received the most attention is cognitive behavioral therapy (CBT). Relatively few trials have been completed and this paper reviews the existing trials. Implications of these trials for the treatment of this early phase as well as for designing future studies are discussed.
Keywords: Cognitive behavioral therapy, prodromal psychosis, psychotic disorders, pre-psychotic period, ultra-high-risk criteria (UHR), Comprehensive Assessment of At Risk Mental State (CAARMS), antipsychotics, stress management, attenuated symptoms, psychological treatments
Current Pharmaceutical Design
Title: Cognitive Behavioral Therapy in Prodromal Psychosis
Volume: 18 Issue: 4
Author(s): Jean Addington, Catherine Marshall and Paul French
Affiliation:
Keywords: Cognitive behavioral therapy, prodromal psychosis, psychotic disorders, pre-psychotic period, ultra-high-risk criteria (UHR), Comprehensive Assessment of At Risk Mental State (CAARMS), antipsychotics, stress management, attenuated symptoms, psychological treatments
Abstract: There is a strong impetus in the psychosis research field to develop interventions that aim to prevent the onset of psychotic disorders. Over the past 15 years there has been a tremendous development in the work aimed at understanding the pre-psychotic period. More recently there has been a focus on developing and testing treatments both pharmacological and psychological that could potentially prevent or delay the onset of psychosis. One of the psychological treatments that has received the most attention is cognitive behavioral therapy (CBT). Relatively few trials have been completed and this paper reviews the existing trials. Implications of these trials for the treatment of this early phase as well as for designing future studies are discussed.
Export Options
About this article
Cite this article as:
Addington Jean, Marshall Catherine and French Paul, Cognitive Behavioral Therapy in Prodromal Psychosis, Current Pharmaceutical Design 2012; 18 (4) . https://dx.doi.org/10.2174/138161212799316082
DOI https://dx.doi.org/10.2174/138161212799316082 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design Endothelin Receptor Antagonists: A New Therapeutic Option for Improving the Outcome after Solid Organ Transplantation?
Current Vascular Pharmacology Monoamine Oxidases: The Biochemistry of the Proteins As Targets in Medicinal Chemistry and Drug Discovery
Current Topics in Medicinal Chemistry Glucose Tolerance: Hypothesis Testing on Malaysian Diabetic Community
Current Diabetes Reviews Animal Models for Investigating Benign Essential Blepharospasm
Current Neuropharmacology Fermented Grape Marc (FGM): Immunomodulating Properties and its Potential Exploitation in the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Interaction Between Platelets and Cytokines - A Possible Role in the Pathogenesis of Preeclampsia
Vascular Disease Prevention (Discontinued) Post-stroke Depression Therapy: Where are we now?
Current Neurovascular Research Vasopressin Receptor Antagonists in Heart Failure
Recent Patents on Cardiovascular Drug Discovery Role of C-Type Lectins in Mycobacterial Infections
Current Drug Targets Alteration of the Proline at Position 7 of the HIV-1 Spacer Peptide p1 Suppresses Viral Infectivity in a Strain Dependent Manner
Current HIV Research Gender Differences in Pharmacokinetics and Side Effects of Second Generation Antipsychotic Drugs
Current Neuropharmacology Monoclonal Antibodies: A New Era in the Treatment of Non-Hodgkins Lymphoma
Current Pharmaceutical Biotechnology Genomic and Epigenomic Instability, Fragile Sites, Schizophrenia and Autism
Current Genomics Enhanced Free Radical Status of Cancer Cells Success and Failure of Prooxidant/Antioxidant Treatment
Current Signal Transduction Therapy Small Molecules and Alzheimer’s Disease: Misfolding, Metabolism and Imaging
Current Alzheimer Research An Efficacy and Safety Study of Remogliflozin in Obese Indian Type 2 Diabetes Mellitus Patients Who Were Inadequately Controlled on Insulin Glargine Plus other Oral Hypoglycemic Agents
Current Diabetes Reviews The Role of B Cell Receptor Stimulation in CLL Pathogenesis
Current Pharmaceutical Design Soluble Forms of RAGE in Human Diseases: Clinical and Therapeutical Implications
Current Medicinal Chemistry Clinical Herbal Interactions with Conventional Drugs: From Molecules to Maladies
Current Medicinal Chemistry